Related Experiment Video
Updated: Jun 23, 2026

08:49
Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
Published on: May 11, 2018
HeartWare miniature axial-flow ventricular assist device: design and initial feasibility test.
Mark S Slaughter1, Michael A Sobieski, Daniel Tamez
1Mechanical Assist Device Program, Advocate Christ Medical Center, Oak Lawn, IL 60453, USA. mscabg@aol.com
Texas Heart Institute Journal
|May 14, 2009
Summary
The HeartWare miniature ventricular assist device shows promise for long-term cardiac support. A 30-day calf study demonstrated no mechanical failures or blood clots, suggesting improved outcomes for patients needing ventricular assist devices.
Area of Science:
- Cardiovascular Engineering
- Biomedical Devices
- Medical Technology
Background:
- Pulsatile ventricular assist devices (VADs) have limitations despite clinical success.
- Continuous-flow VADs offer improvements but design enhancements are still needed for long-term left ventricular support.
- The HeartWare miniature VAD represents a novel axial-flow pump design.
Purpose of the Study:
- To evaluate the feasibility and performance of the HeartWare miniature ventricular assist device.
- To assess the safety and hemodynamic effects of the device in an animal model.
- To explore the potential benefits of this new VAD technology for broader clinical application.
Main Methods:
- Implantation of the HeartWare miniature VAD in a calf model.
- Continuous monitoring of device performance and hemodynamic parameters for 30 days.
- Post-explantation analysis including mechanical assessment and thrombus evaluation, alongside a full autopsy.
Main Results:
- The miniature VAD operated successfully for 30 days without mechanical failure.
- No thrombi were observed upon device explantation.
- The animal model maintained stable circulation and showed no end-organ abnormalities post-autopsy.
Conclusions:
- The HeartWare miniature VAD demonstrates promising safety and efficacy in a preclinical setting.
- Potential benefits include wider patient accessibility, reduced infection risk, and simpler implantation.
- Further in vivo studies are warranted to support potential human clinical trials.

